psalexa
SearchBar Icon

Breast Biopsy Devices Market to Reach $1.4 Billion by 2023

Published Date:   February 2018

Global breast biopsy devices market is forecasted to generate a revenue of $1.4 billion by 2023, P&S Market Research

The growth is mainly led by product and technological innovations, increasing incidence of breast cancer cases, rising propensity for minimally invasive surgeries, and mounting number of breast cancer screening programs.

Browse Report Summary with Deailed TOC on "Breast Biopsy Devices Market by Product (Guidance Systems, Biopsy Needles/Guns, Biopsy Tables, Biopsy Wires), by Procedure Type (Vacuum-Assisted, Core Needle, Fine Needle Aspiration, Surgical), by Imaging Modality (Mammography Guided Stereotactic, Ultrasound, MRI, CT), by End-User (Diagnostic Centers, Hospitals), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Japan, China, India, Australia, Brazil, Mexico) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013–2023" at: https://www.psmarketresearch.com/market-analysis/breast-biopsy-devices-market

Insights on market segments

On the basis of the procedure conducted for breast biopsy, the market is categorized into vacuum-assisted, core needle, fine needle aspiration, and surgical biopsy. Vacuum-assisted biopsies have been accounting for the largest share in the breast biopsy devices market till now. It is also expected to be the fastest growing category during the forecast period. This can be mainly attributed to its various advantages, such as its ability to precisely locate the area of abnormality using imaging guidance, so that samples are removed only from the region of interest.

On the basis of product, the breast biopsy devices market has been segmented into guidance systems, biopsy needles/guns, biopsy tables, biopsy wires, and other products. Guidance systems are estimated to hold the largest share of 40.1%, in the market in 2017, with its demand majorly driven by the availability of stereotactic breast biopsy and tomosynthesis options in a single system, and the requirement of these systems in all types of surgeries.

Different types of imaging modalities are used while performing breast biopsy procedure, such as mammography guided stereotactic biopsy, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and several others. Among these, Mammography guided stereotactic biopsy has been holding the largest share in the breast biopsy devices market till now, as it is a minimally invasive procedure and the needle used does not distort the breast tissue. However, ultrasound guided biopsy is expected to be the fastest growing imaging modality during the forecast period.

Hospitals, diagnostic centers, and other healthcare providers constitute the end-user base in the breast biopsy devices market. Diagnostic centers have been the largest end user in the breast biopsy devices market till now. However, as hospitals are witnessing increasing demand for advanced healthcare facilities and growing healthcare infrastructure, the category is expected to be the fastest growing end-user during the forecast period.

APAC to be the fastest growing market for breast biopsy devices

During the forecast period, the breast biopsy devices industry is expected to witness the fastest growth in in Asia-Pacific (APAC), owing to growing geriatric population, increasing prevalence of breast cancer, growing awareness about breast cancer, rising healthcare expenditure, per capita income, and increasing research in breast biopsy devices in the region. According to National Institute of Cancer Prevention and Research, breast cancer is the most common cancer in women in India and accounts for about a quarter of all cancers in women in Indian cities, and the average age for breast cancer in India is almost a decade lower than that in the West.

According to International Agency for Research on Cancer, in 2012, breast cancer incidences reported in India were 144,937 and the mortality rate in women in India was 70,218, which is comparatively higher than China (47,989). In order to balance these statistics, the government and several other organizations are also creating awareness about breast cancer. For instance, October has been designated as the breast cancer awareness month by the government of India, which is an annual campaign to educate people about breast cancer. Also, the Pink Initiative, a registered charity in Mumbai, creates awareness about breast cancer amongst women in India. These factors cumulatively lead to growth in the demand of breast biopsy devices in the region.

Breast biopsy surgeries are cheaper in India and they are also witnessing an increase in the research and development for the treatment of breast cancer, which is ultimately propelling the growth of the breast biopsy devices market in the region. For instance, a team of researchers from Tohoku University, in January 2016, developed a new method to detect breast cancer by combining a mammogram with an ultrasound in a procedure that appears to be more accurate than mammogram testing alone.

Key players launching new products for market expansion

Globally, key players in the breast biopsy devices industry are launching products to gain a larger market share. For instance, in November 2017, Siemens Healthineers, a subsidiary of Siemens AG, unveiled its new Mammomat Revelation imaging system at the 2017 Radiological Society of North America (RSNA) Annual Meeting in Chicago. 3D HD Breast Biopsy uses company’s 50-degree wide-angle HD breast tomosynthesis to obtain more targeted, accurate biopsies at a lower dose. The system also offers titanium contrast-enhanced mammography exams and automated breast density measurement.

In August 2017, Hologic Inc. announced the commercial availability of Brevera breast biopsy system with CorLumina imaging technology, in the U.S. The Brevera system provides clinicians with more information at the point of care and results in significant cost and time savings without compromising with accuracy or patient health outcomes.

Some of the other major players operating in the breast biopsy devices market include Danaher Corporation, Argon Medical Devices Inc., Becton, Dickinson and Company, Sterylab S.R.L., Scion Medical Technologies LLC, Planmed Oy, Medtronic plc, and Cook Medical LLC.

GLOBAL BREAST BIOPSY DEVICES MARKET SEGMENTATION

Market Segmentation by Product

  • Guidance Systems
  • Biopsy Needles/Guns
  • Biopsy Tables
  • Biopsy Wires
  • Others

Market Segmentation by Procedure Type

  • Vacuum-Assisted Biopsy
  • Core Needle Biopsy
  • Fine Needle Aspiration Biopsy
  • Surgical Biopsy

Market Segmentation by Imaging Modality

  • Mammography Guided Stereotactic Biopsy
  • Ultrasound Guided Biopsy
  • Magnetic Resonance Imaging (MRI) Guided Biopsy
  • Computed Tomography (CT) Guided Biopsy
  • Others

Market Segmentation by Geography

  • North America Breast Biopsy Devices Market
    • By Product
    • By Procedure Type
    • By Imaging Modality
    • By Country – U.S. and Canada
  • Europe Breast Biopsy Devices Market
    • By Product
    • By Procedure Type
    • By Imaging Modality
    • By Country – Germany, France, U.K., Italy, Spain, and Rest of Europe
  • Asia-Pacific (APAC) Breast Biopsy Devices Market
    • By Product
    • By Procedure Type
    • By Imaging Modality
    • By Country – Japan, China, India, Australia and Rest of APAC
  • Rest of the World (RoW) Breast Biopsy Devices Market
    • By Product
    • By Procedure Type
    • By Imaging Modality
    • By Country – Brazil, Mexico and Rest of RoW